Emerging treatments for hypertension: Potential role for vasopeptidase inhibition

American Journal of Hypertension

Volumn 12, Issue 11 SUPPL. 1, 1999, Pages

  Weber, Michael ^a  

^a BROOKDALE UNIVERSITY HOSPITAL AND MEDICAL CENTER   (United States)

Author keywords

Hypertension; Omapatrilat; Vasopeptidase inhibitors

Indexed keywords

7 (2 MERCAPTOMETHYL 3 PHENYLPROPIONAMIDO)HEPTANOIC ACID; ANGIOTENSIN; ANTIHYPERTENSIVE AGENT; DIPEPTIDYL CARBOXYPEPTIDASE; LEUCINE THIORPHAN; MEMBRANE METALLOENDOPEPTIDASE; N (2 MERCAPTOMETHYL 3 PHENYLBUTYRYL)ALANINE; N [2 (ACETYLTHIOMETHYL) 3 (2 METHYLPHENYL)PROPIONYL]METHIONINE ETHYL ESTER; N [[1 (2 ACETYLTHIO 3 METHYL 1 OXOBUTYLAMINO) 1 CYCLOPENTYL]CARBONYL] O METHYLTYROSINE ETHYL ESTER; NATRIURETIC FACTOR; OMAPATRILAT; PROTEINASE INHIBITOR; RENIN; UNCLASSIFIED DRUG; VASOPEPTIDASE INHIBITOR;

ANTIHYPERTENSIVE THERAPY; BLOOD PRESSURE REGULATION; CONGESTIVE HEART FAILURE; DOSE RESPONSE; DRUG EFFICACY; DRUG MECHANISM; HUMAN; HYPERTENSION; INTRAVENOUS DRUG ADMINISTRATION; NONHUMAN; ORAL DRUG ADMINISTRATION; PLASMA RENIN ACTIVITY; PRIORITY JOURNAL; PROTEIN SYNTHESIS INHIBITION; PROTEINASE INHIBITION; REVIEW; SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME; URINARY EXCRETION;

ANGIOTENSIN II; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; BIOLOGICAL MARKERS; BLOOD PRESSURE; HEART FAILURE, CONGESTIVE; HUMANS; HYPERTENSION; PYRIDINES; RENIN; SURVIVAL RATE; THIAZEPINES; TREATMENT OUTCOME; VASODILATION;

EID: 0032712735     PISSN: 08957061     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0895-7061(99)00205-8     Document Type: Article

References (57)

1. Materson BJ, Reda DJ, Cushman WC, Massie BM, Freis ED, Kochar MS, Hamburger RJ, Fye C, Lakshman R, Gottdiener J, Ramirez EA, Henderson WG, for the Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents: Single-drug therapy for hypertension in men. A comparison of six antihypertensive agents with placebo [published erratum appears in N Engl J Med 1994;330:1689]. N Engl J Med 1993;328:914-921.
2. Perry HMJ, Bingham S, Horney A, Rutan G, Sambhi M, Carmody S, Collins J, for the Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents: Antihypertensive efficacy of treatment regimens used in Veterans Administration hypertension clinics. Hypertension 1998;31:771-779.
3. Guidelines Subcommittee: 1999 World Health Organization-International Society of Hypertension Guidelines for the management of hypertension. J Hypertens 1999;17:151-183.
4. Kannel WB, Dawber TR, McGee DL: Perspectives on systolic hypertension. The Framingham study. Circulation 1980;61:1179-1182.
5. Sagie A, Larson MG, Levy D: The natural history of borderline isolated systolic hypertension. N Engl J Med 1993;329:1912-1917.
6. Launer LJ, Masaki K, Petrovitch H, Foley D, Havlik RJ: The association between midlife blood pressure levels and late-life cognitive function. JAMA 1995;274:1846-1851.
7. SHEP Cooperative Research Group: Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA 1991;265:3255-3264.
8. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD, for the Collaborative Study Group: The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy [published erratum appears in N Engl J Med 1993;330: 152]. N Engl J Med 1993;329:1456-1462.
9. Williams GH: Aldosterone: new concepts in mechanism of action (abst). Am J Hypertens 1999;12(Pt 2): 226A.
10. Funder JW: Epithelial and non-epithelial effects on mineralocorticoids (abst). Am J Hypertens 1999;12(Pt 2):226A.
11. Williams GH: Aldosterone: antagonists and cardiovascular protection (abst). Am J Hypertens 1999;12(Pt 2): 213A.
12. Fisher NDL, Hurwitz S, Ferri C, Jeunmaitre X, Hollenberg NK, Williams GH: Altered adrenal sensitivity to angiotensin II in low renin essential hypertension (abst). Am J Hypertens 1999;12(Pt 2):36A.
13. Frishman WH: Imidazoline receptor agonist drugs (abst). Am J Hypertens 1999;12(Pt 2):213A.
14. Wada A, Tsutamoto T, Ohnishi M, Sawaki M, Fukai D, Maeda Y, Kinoshita M: Effects of a specific endothelin-converting enzyme inhibitor on cardiac, renal, and neurohumoral functions in congestive heart failure: comparison of effects with those of endothelin A receptor antagonism. Circulation 1999;99:570-577.
15. Schiffrin EL: Endothelin and endothelin antagonists in hypertension. J Hypertens 1998;16(Pt 2):1891-1895.
16. Zeiher AM, Krause T, Schächinger V, Minners J, Moser E: Impaired endothelium-dependent vasodilation of coronary resistance vessels is associated with exercise-induced myocardial ischemia. Circulation 1995;91: 2345-2352.
17. Burnett JC Jr: Vasopeptidase inhibition: a new concept in blood pressure management. J Hypertens 1999; 17(suppl 1):S37-S43.
18. Levin ER, Gardner DG, Samson WK: Natriuretic peptides. N Engl J Med 1998;339:321-328.
19. Schweitz H, Vigne P, Moinier D, Frelin C, Lazdunski M: A new member of the natriuretic peptide family is present in the venom of the green mamba (Dendroaspis angusticeps). J Biol Chem 1992;267:13928-13932.
20. Maack T, Suzuki M, Almeida FA, Nussenzveig D, Scarborough RM, McEnroe GA, Lewicki JA: Physiological role of silent receptors of atrial natriuretic factor. Science 1987;238:675-678.
21. Ruschitzka F, Corti R, Noll G, Lüscher TF: A rationale for treatment of endothelial dysfunction in hypertension. J Hypertens 1999;17(suppl 1):S25-S35.
22. Chen HH, Burnett JC Jr: C-type natriuretic peptide: the endothelial component of the natriuretic peptide system. J Cardiovasc Pharmacol 1998;32(suppl 3):S22-S28.
23. Wilkins MR, Unwin RJ, Kenny AJ: Endopeptidase-24.11 and its inhibitors: potential therapeutic agents for edematous disorders and hypertension. Kidney Int 1993;43:273-285.
24. Erdös EG, Skidgel RA: Neutral endopeptidase 24.11 (enkephalinase) and related regulators of peptide hormones. FASEB J 1989;3:145-151.
25. González W, Soleilhac J-M, Fournié-Zaluski M-C, Roques BP, Michel J-B: Characterization of neutral endopeptidase in vascular cells, modulation of vasoactive peptide levels. Eur J Pharmacol 1998;345:323-331.
26. Wilcox JN, Augustine A, Goeddel DV, Lowe DG: Differential regional expression of three natriuretic peptide receptor genes within primate tissues. Mol Cell Biol 1991;11:3454-3462.
27. Robl JA, Sun CQ, Stevenson J, Ryono DE, Simpkins LM, Cimarusti MP, Dejneka T, Slusarchyk WA, Chao S, Stratton L, Misra RN, Bednarz MS, Asaad MM, Cheung HS, Abboa-Offei BE, Smith PL, Mathers PD, Fox M, Schaeffer TR, Seymour AA, Trippodo NC: Dual metalloprotease inhibitors: mercaptoacetyl-based fused heterocyclic dipeptide mimetics as inhibitors of angiotensin-converting enzyme and neutral endopeptidase. J Med Chem 1997;40:1570-1577.
28. Saxenhofer H, Raselli A, Weidmann P, Forssmann WG, Bub A, Ferrari P, Shaw SG: Urodilantin, a natriuretic factor from kidneys, can modify renal and cardiovascular function in men. Am J Physiol 1990;259(Pt 2): F832-F838.
29. Blais CJ, Drapeau G, Raymond P, Lamontagne D, Gervais N, Venneman I, Adam A: Contribution of angiotensin-converting enzyme to the cardiac metabolism of bradykinin: an interspecies study. Am J Physiol 1997; 273(Pt 2):H2263-H2271.
30. Ishida H, Scicli AG, Carretero OA: Role of angiotensin converting enzyme and other peptidases in in vivo metabolism of kinins. Hypertension 1989;14:322-327.
31. Danser AHJ, Admiraal PJJ, Derkx FHM, Schalekamp MADH: Angiotensin I-to-II conversion in the human renal vascular bed. J Hypertens 1998;16(Pt 2):2051-2056.
32. Trippodo NC, Robl JA, Asaad MM, Bird JE, Panchal BC, Schaeffer TR, Fox M, Giancarli MR, Cheung HS: Cardiovascular effects of the novel dual inhibitor of neutral endopeptidase and angiotensin-converting enzyme BMS-182657 in experimental hypertension and heart failure. J Pharmacol Exp Ther 1995;275:745-752.
33. Seymour AA, Swerdel JN, Abboa-Offei B: Antihypertensive activity during inhibition of neutral endopeptidase and angiotensin converting enzyme. J Cardiovasc Pharmacol 1991;17:456-465.
34. Tikkanen T, Tikkanen I, Rockwell MD, Allen TJ, Johnston CI, Cooper ME, Burrell LM: Dual inhibition of neutral endopeptidase and angiotensin-converting enzyme in rats with hypertension and diabetes mellitus. Hypertension 1998;32:778-785.
35. Cohen DS, Mathis JE, Dotson RA, Graybill SR, Wosu NJ: Protective effects of CGS 30440, a combined angiotensin-converting enzyme inhibitor and neutral endopeptidase inhibitor, in a model of chronic renal failure. J Cardiovasc Pharmacol 1998;32:87-95.
36. Margulies KB, Perrella MA, McKinley LJ, Burnett JCJ: Angiotensin inhibition potentiates the renal responses to neutral endopeptidase inhibition in dogs with congestive heart failure. J Clin Invest 1991;88:1636-1642.
37. Seymour AA, Asaad MM, Lanoce VM, Langenbacher KM, Fennell SA, Rogers WL: Systemic hemodynamics, renal function and hormonal levels during inhibition of neutral endopeptidase 3.4.24.11 and angiotensin-converting enzyme in conscious dogs with pacing-induced heart failure. J Pharmacol Exp Ther 1993;266:872-883.
38. Trippodo NC, Fox M, Natarajan V, Panchal BC, Dorso CR, Asaad MM: Combined inhibition of neutral endopeptidase and angiotensin converting enzyme in cardiomyopathic hamsters with compensated heart failure. J Pharmacol Exp Ther 1993;267:108-116.
39. Flynn GA, French JF, Dage RC: Dual inhibitors of angiotensin-converting enzyme and neutral endopeptidase: design and therapeutic rationale, in Laragh JH, Brenner BM (eds): Hypertension: Pathophysiology, Diagnosis, and Management. New York, Raven Press, 1995, pp 3099-3114.
40. Andó S, Rahman MA, Butler GC, Senn BL, Floras JS: Comparison of candoxatril and atrial natriuretic factor in healthy men. Effects on hemodynamics, sympathetic activity, heart rate variability, and endothelin. Hypertension 1995;26(Pt 2):1160-1166.
41. Richards AM, Crozier IG, Espiner EA, Ikram H, Yandle TG, Kosoglou T, Rallings M, Frampton C: Acute inhibition of endopeptidase 24.11 in essential hypertension: SCH 34826 enhances atrial natriuretic peptide and natriuresis without lowering blood pressure. J Cardiovasc Pharmacol 1992;20:735-741.
42. Bevan EG, Connell JMC, Doyle J, Carmichael HA, Davies DL, Lorimer AR, Mclnnes GT: Candoxatril, a neutral endopeptidase inhibitor: efficacy and tolerability in essential hypertension. J Hypertens 1992;10:607-613.
43. Richards AM, Wittert GA, Espiner EA, Yandle TG, Ikram H, Frampton C: Effect of inhibition of endopeptidase 24.11 on responses to angiotensin II in human volunteers. Circ Res 1992;71:1501-1507.
44. Richards AM, Wittert GA, Crozier IG, Espiner EA, Yandle TG, Ikram H, Frampton C: Chronic inhibition of endopeptidase 24.11 in essential hypertension: evidence for enhanced atrial natriuretic peptide and angiotensin II. J Hypertens 1993;11:407-416.
45. Stergiou GS, Hannah JA, Bevan EG, Lorimer AR, Carmichael HA, Hettiarachchi J, McInnes GT: Combined atriopeptidase inhibition and angiotensin converting enzyme inhibition in hypertensive patients (abst). J Hypertens 1994;12:1310-1311.
46. Fink CA: Recent advances in the development of dual angiotensin-converting enzyme and neutral endopeptidase inhibitors. Exp Opin Ther Patents 1996;6:1147-1164.
47. Wallis EJ, Ramsay LE, Hettiarachchi J: Combined inhibition of neutral endopeptidase and angiotensin-converting enzyme by sampatrilat in essential hypertension. Clin Pharmacol Ther 1998;64:439-449.
48. Norton G, Woodiwiss A, Hartford C, Trifunovic B, Middlemost S, Lee A, Allen MJ: Sustained antihypertensive actions of a dual angiotensin-converting enzyme neutral endopeptidase inhibitor, sampatrilat, in black hypertensive subjects. Am J Hypertens 1999;12: 563-571.
49. Trippodo NC, Robl JA, Asaad MM, Fox M, Panchal BC, Schaeffer TR: Effects of omapatrilat in low, normal, and high renin experimental hypertension. Am J Hypertens 1998;11:363-372.
50. Trippodo NC, Fox M, Monticello TM, Panchal BC, Asaad MM: Simultaneous inhibition of neutral endopeptidase and angiotensin converting enzyme by omapatrilat increased survival in heart failure hamsters greater than ACE inhibition (abst 4095). Circulation 1998;98:I-781.
51. Thomas CV, McDaniel GM, Holzgrefe HH, Mukherjee R, Hird RB, Walker JD, Hebbar L, Powell JR, Spinale FG: Chronic dual inhibition of angiotensin-converting enzyme and neutral endopeptidase during the development of left ventricular dysfunction in dogs. J Cardiovasc Pharmacol 1998;32:902-912.
52. Vesterqvist O, Liao W, Manning JA, Uderman H, Delaney C, Beierle F, Swanson BN: Effects of BMS-186716, a new dual metalloprotease inhibitor, on pharmacodynamic markers of neutral endopeptidase (NEP) and angiotensin converting enzyme (ACE) activity in healthy men (abst PIV-46). Clin Pharmacol Ther 1997; 61:230.
53. Liao W, Delaney C, Smith R, Lubin S, McNulty S, Davis K, Meier A, Uderman H: Supine mean arterial blood pressure (MAP) lowering and oral tolerance of BMS-186716, a new dual metalloprotease inhibitor of angiotensin converting enzyme (ACE) and neutral endopeptidase (NEP), in healthy male subjects (abst PIV-45). Clin Pharmacol Ther 1997;61:229.
54. Ruddy M, Guthrie R, Papademetriou V, Moulton K, Saini R: The safety and 24-hour antihypertensive efficacy of the vasopeptidase inhibitor omapatrilat: a pilot study (abst D059). Am J Hypertens 1999;12(Pt 2):125A.
55. Zusman R, Atlas S, Kochar M, Adler E, Levy E: Efficacy and safety of omapatrilat, a vasopeptidase inhibitor (abst D060). Am J Hypertens 1999;12(Pt 2):125A.
56. Weber MA, Chang PI, Reeves RA, Moulton K, Pouleur H: Antihypertensive dose response of omapatrilat, a vasopeptidase inhibitor, in mild to moderate hypertension (abst D046). Am J Hypertens 1999;12(Pt 2):122A.
57. Black HR, Chang PI, Reeves RA, Cooper W, Pouleur H: Monotherapy treatment success rate of omapatrilat, a vasopeptidase inhibitor, compared with lisinopril and amlodipine in mild to moderate hypertension (abst). Am J Hypertens 1999;12(Pt 2):26A.